Lotus Reports March 2026 Revenue of NT$4,354 Million

Taipei, Taiwan, 10 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for March 2026 of NT$4,354 million, representing an increase of 174% YoY, mainly driven by the consolidation of Alvogen as well as the strong growth in our B2B business. Lotus's year-to-date (YTD) March 2026 revenue reached NT$8,644 million, an increase of 83% compared to the same period last year, helped by the same growth drivers.

For the first three months ending March 2026, revenue from Lotus’ Asia business grew 5% to NT$2,741 million, representing c.32% of the Group’s total consolidated revenue, supported by the SEA and Korea markets. Alvogen, our newly acquired business for the US market, delivered revenue of NT$4,926 million for the same period, representing c.57% of the total consolidated revenue. Performance for the month of March was stronger compared to previous months, reflecting customer purchasing patterns during the quarter for major products. Lotus’ B2B business grew 408% YoY to NT$977 million, contributing c.11% to total consolidated revenue, mainly driven by the incremental contribution from Nintedanib in the EU as well as the increased sales of Enzalutamide in South America and Canada.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness